Is This Under-the-Radar Stock a Better Coronavirus Play Than Moderna?
You don't have to be an infectious disease expert to know that Moderna (NASDAQ: MRNA) ranks among the leaders in developing a novel coronavirus vaccine. Moderna's mRNA-1273 vaccine was on the shortlist of COVID-19 vaccine candidates to receive federal funding as part of Operation Warp Speed. World Health Organization chief scientist Soumya Swaminathan thinks Moderna is in a close second place behind AstraZeneca in the race to develop a COVID-19 vaccine.
